You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Novel CGRP Monoclonal Antibodies and CGRP Receptor Antagonists: A Recipe for Success in Migraine Prevention and Treatment

  • Authors: Stephanie J. Nahas, MD, MSEd, FAHS, FAAN; Shirley Kessel, BS
  • CME / CE Released: 2/3/2023
  • Valid for credit through: 2/3/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    Nurses - 1.00 CABN Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Physician Assistant - 1.00 AAPA hour(s) of Category I credit

    IPCE - 1.0 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for neurologists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with neurological conditions.

The goal of this activity is for learners to be better able to understand the recent research suggesting that taking calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) combined with CGRP receptor antagonists (RAs [gepants]) appears to be safe and effective for migraine. Emerging evidence like this is very promising for patients who suffer from this debilitating neurological condition. This session will explore the use of novel CGRP mAbs and CGRP receptor antagonists for the management of migraine.

Upon completion of this activity, participants will:

  1. Describe the prevalence and key causes of suboptimal migraine management despite available treatment options.
  2. Evaluate the mechanisms of action, most recent efficacy and safety data, and administration considerations associated with current and emerging therapies for the treatment and prevention of migraine.
  3. Assess patient response to current therapy and integrate novel migraine therapies as appropriate into patient-centered care strategies.


HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and; any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, identified those with the potential to compromise the goals and educational integrity of the education and mitigated any conflict of interest. Relevant relationships, or lack thereof, are shared with the learner.

Supported education has been independently peer-reviewed to validate content and faculty with relevant relationships have attested that:

All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.

All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.

Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.


  • Stephanie J. Nahas, MD, MSEd, FAHS, FAAN

    Associate Professor of Neurology
    Department of Neurology
    Director, Headache Medicine Fellowship Program
    Jefferson Headache Center
    Thomas Jefferson University
    Philadelphia, Pennsylvania


    Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, has the following relevant financial relationships:
    Consultant or advisor for: Alder/Lundbeck; Allergan/AbbVie; Amgen/Novartis; Biohaven; Eli Lilly; Teva
    Speaker or member of speakers bureau for: Allergan/AbbVie; Amgen/Novartis; Eli Lilly; Teva
    Research funding from: Teva

  • Shirley Kessel, BS

    Executive Director
    Miles for Migraine
    Jericho, Vermont


    Shirley Kessel, BS, has the following relevant financial relationships:
    Consultant or advisor for: Alder/Lundbeck; Allergan/AbbVie

Additional Planners/Reviewers

  • William C. Torrey, MD

    Professor and Vice Chair for Clinical Services
    Dartmouth’s Geisel School of Medicine, Dartmouth-Hitchcock
    Lebanon, New Hampshire


    William C. Torrey, MD, has no relevant financial relationships.

HMP Education planners and staff include Samantha Joy, Molly Duda, Kathleen Hines, Mary Johnson, Randy Robbin, Michelle Stewart, Joanna Tong, and Andrea Zimmerman. 

No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration).

- Applicable CME staff have no relationships to disclose relating to the subject matter of this activity.

This activity has been independently reviewed for balance.

Accreditation Statements

Interprofessional Continuing Education

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • HMP Education designates this Internet enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 



    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Contact This Provider

    For Nurses

  • This continuing nursing education live/internet live/internet enduring activity awards 1.0 contact hours.

    Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hours.

    Contact This Provider

  • For Physician Assistants

    HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credits. Approval is valid until February 3, 2024. PAs should only claim credit commensurate with the extent of their participation.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

Grievance Policy

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Joy, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at [email protected] or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Joy will review the grievance and respond within 30 days of receiving the complaint.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 66% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Novel CGRP Monoclonal Antibodies and CGRP Receptor Antagonists: A Recipe for Success in Migraine Prevention and Treatment

Authors: Stephanie J. Nahas, MD, MSEd, FAHS, FAAN; Shirley Kessel, BSFaculty and Disclosures

CME / CE Released: 2/3/2023

Valid for credit through: 2/3/2024, 11:59 PM EST


Assessment Survey

Before you begin, please take this brief survey.

  • Print